Chasing my Cure: Leveraging serum proteomics to identify novel therapeutic approaches and predictive biomarkers
20 January 2022
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Watch our on-demand one-hour session to discover groundbreaking work to advance precision medicine for Castleman disease.
About this webinar
Dr David Fajgenbaum, the Founding Director of the Center for Cytokine Storm Treatment & Laboratory at the University of Pennsylvania and national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action, shares his groundbreaking work to advance precision medicine for Castleman disease, a cytokine storm disorder that he is battling as a physician, researcher, advocate and patient. Combining SomaScan proteomic and other -omic analyses with cutting-edge bioinformatic approaches, Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others.
Learning outcomes of this webinar
- The potential for unbiased serum proteomic analyses to improve understanding of the pathologic mechanisms of a poorly understood, inflammatory disease (idiopathic multicentric Castleman disease)
- How SomaScan can be leveraged to discover biomarkers that can predict which patients will respond to a given treatment
- How SomaScan can be leveraged to identify novel therapeutic targets and promising new or repurposed treatment approaches
- The importance of academic-industry-advocacy collaborations to leverage biospecimens collected from clinical trials to improve understanding and treatment of rare disorders.
Our speaker
David Fajgenbaum, MD, MBA, MSc
Assistant Professor of Medicine, Translational Medicine & Human Genetics, University of Pennsylvania
Founding Director, Center for Cytokine Storm Treatment & Laboratory (CSTL)
Associate Director, Patient Impact, Orphan Disease Center, University of Pennsylvania
Co-Founder & President, Castleman Disease Collaborative Network (CDCN)
David Fajgenbaum, MD, MBA, MSc, is an Assistant Professor of Medicine at the University of Pennsylvania, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director of Patient Impact for the Penn Orphan Disease Center and co-Founder/President of the Castleman Disease Collaborative Network (CDCN). He is also the national bestselling author of ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action’ and a patient battling idiopathic multicentric Castleman disease (iMCD). He is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD. Fajgenbaum launched the CORONA project in March 2020 to identify and track treatments for COVID-19. Today, CORONA is the world’s largest database of COVID-19 treatments, including more than 400 medications that have been administered to more than 280,000 patients. Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Investigation and Blood. To advance drug repurposing, he is co-directing an FDA/NIH/C-Path public-private partnership called the CURE Drug Repurposing Collaboratory and leading an effort for rare disease repurposing in collaboration with the Chan Zuckerberg Initiative.